Clinical and Cell Biological Features Related to Cellular Drug Resistance of Childhood Acute Lymphoblastic Leukemia Cells

References

• Clavell L. A., Gelber R. D., Cohen H. J., Hitchcock-Bryan S., Cassady J. R., Tarbell N. J., Blattner S. R., Tantravahi R., Leavitt P., Sallan S. E. Four-agent induction and intensive as-paraginase therapy for treatment of childhood acute lymphoblastic leukemia. N. Eng. J. Med. 1986; 315: 657–663
   PubMed Web of Science ®Google Scholar
• Rivera G. K., Raimondi S. C., Hancock M. L., Behm F. G., Pui C.-H., Abrornowitch M., Mirro J., Jr, Ochs J. S., Look T. A., Williams D. L., Murphy S. B., Dahl G. V., Kalwinsky D. K., Evans W. E., Kun L. E., Simone J. V., Crist W. M. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337: 61–66
   PubMed Web of Science ®Google Scholar
• Hammond G. D. Leukemia cell DNA content: predictor of late relapse in acute lymphoblastic leukemia. J. CIin. Oncol. 1991; 9: 1332–1333
   PubMed Web of Science ®Google Scholar
• Hammond D., Sather H., Nesbit M., Miller D., Coccia P., Bleyer A., Lukens J., Siegel S. Analysis of prognostic factors in acute lymphoblastic leukemia. Med. Pediatr. Oncol. 1986; 14: 124–134
   PubMedGoogle Scholar
• Poplack D. G., Reaman G. Acute lymphoblastic leukemia in childhood. Pediatr. Clinics North Am. 1988; 35: 903–932
   Web of Science ®Google Scholar
• Pieters R., Kaspers G. J. L., Van Wering E. R., Huismans D. R., Loonen A. H., Hählen K., Veerman A. J. P. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype, age and sex in childhood acute lymphoblastic leukemia. Leukemia 1993; 7: 392–397
   PubMed Web of Science ®Google Scholar
• Veerman A. J. P., Pieters R. Drug sensitivity assays in leukaemia and lymphoma. Br. J. Haematol. 1990; 74: 381–384
   PubMed Web of Science ®Google Scholar
• Hongo T., Fujii Y., Igarashi Y. An in vitro chemosensitivity test for the screening of anticancer drugs in childhood leukemia. Cancer 1990; 65: 1263–1272
   PubMed Web of Science ®Google Scholar
• Kaspers G. J. L., Pieters R., Van Zantwijk C. H., De Waal F. C., Van Wering E. R., Veerman A. J. P. Is resistance to prednisolone in vitro related to the response to prednisolone at initial diagnosis in childhood acute lymphoblastic leukemia? A preliminary analysis. Drug resistance in leukemia and lymphoma—The clinical value of laboratory assays, G. J. L. Kaspers, R. Pieters, P. R. Twentyman, L. M. Weisenthal, A. J. P. Veerman. Chur. Harwood Academic Publ. 1993; 321–328
   Google Scholar
• Kaspers G. J. L., Pieters R., Van Zantwijk C. H., Van Wering E. R., Van Der Does-Van Den Berg A., Veerman A. J. P. Resistance to prednisolone (PRD) in vitro: A new prognostic factor in childhood acute lymphoblastic leukemia (ALL) at initial diagnosis. Proc. Am. Soc. Clin. Oncol. 1993; 12: 320, #1061
   Google Scholar
• Pieters R., Huismans D. R., Loonen A. H., Hählen K., Van Der Does-Van DenBerg A., Van Wering E. R., Veerman A. J. P. Relation of cellular drug resistance to longterm clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991; 338: 399–403
   PubMed Web of Science ®Google Scholar
• Sargent J. M., Taylor C. G. Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia. Br. J. Cancer 1989; 60: 206–210
   PubMed Web of Science ®Google Scholar
• Kaspers G. J. L., Kardos G., Pieters R., Van Zantwijk C. H., Klumper E., Hählen K., De Waal F. C., Van Wering E. R., Veerman A. J. P. Different cellular drug resistance profiles in childhood acute lymphoblastic and non-lymphoblastic leukaemia, with emphasis on glucocorticoids. Leukemia 1994; 8: 1224–1229
   PubMed Web of Science ®Google Scholar
• Kaspers G. J. L., Smets L. A., Pieters R., Van Zantwijk C. H., Van Wering E. R., Veerman A. J. P. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetaboliles and other drugs: Results of an in vitro study. Blood 1995; 105: 751–756
   Google Scholar
• Larsson R., Kristensen J., Sandberg C., Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorimetric microculture cytotoxicity assay (FMCA). Int. J. Cancer 1992; 50: 177–185
   PubMed Web of Science ®Google Scholar
• Weisenthal L. M., Dill P. L., Finklestein J. Z., Duarte T. E., Baker J. A., Moran E. M. Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms. Cancer Treatm. Rep. 1986; 70: 1283–1295
   PubMedGoogle Scholar
• Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A. G., Gralnick H. R., Sultan C. The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations. Br. J. Haematol. 1981; 47: 553–561
   PubMed Web of Science ®Google Scholar
• Van Wering E. R., Brederoo P., Van Staalduinen G. J., Van Der Meulen J., Van Der Linden-Schrever B. E. M., Van Dongen J. J. M. Contribution of electron microscopy to the classification of minimally differentiated acute leukemias in children. Recent Results Cancer Res. 1993; 131: 77–87
   PubMedGoogle Scholar
• Kaspers G. J. L., Pieters R., Van Zantwijk C. H., De Laat P. A. J.M., De Waal F. C., Van Wering E. R., Veerman A. J. P. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br. J. Cancer 1991; 64: 469–474
   PubMed Web of Science ®Google Scholar
• Kaspers G. J. L., Veerman A. J. P., Pieters R., Broekema G. J., Huismans D. R., Kazemier K. M., Loonen A. H., Rottier M. M. A., Van Zantwijk C. H., Hählen K., Van Wering E. R. Mononuclear cells contaminating leukemic samples tested for cellular drug resistance using the MTT assay. Br. J. Cancer 1994; 70: 1047–1052
   PubMed Web of Science ®Google Scholar
• Pieters R., Huismans D. R., Leyva A., Veerman A. J. P. Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukemia. Br. J. Cancer 1989; 59: 217–220
   PubMed Web of Science ®Google Scholar
• Kirkpatrick D. L., Duke M., Goh T. S. Chemosensitivity testing of fresh human leukemia cells using both a dye exclusion assay and a tetrazolium dye MTT assay. Leuk. Res. 1990; 14: 459–466
   PubMed Web of Science ®Google Scholar
• Pieters R., Loonen A. H., Huismans D. R., Broekema G. J., Dirven M. W. J., Heyenbrok M. W., Hählen K., Veerman A. J. P. In vitro sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76: 2327–2336
   PubMed Web of Science ®Google Scholar
• Pieters R., Huismans D. R., Leyva A., Veerman A. J. P. Adaptation of the rapid automated tetrazolium dye based MTT assay for chemosensitivity testing in childhood leukemia. Cancer Lett. 1988; 41: 323–332
   PubMed Web of Science ®Google Scholar
• Crist W., Boyett J., Jackson J., Vietti T., Borowitz M., Chauvenet A., Winick N., Ragab A., Mahoney D., Head D., Iyer R., Wagner H., Pullen J. Prognostic importance of the pre-B-cell immunophenotype and other presenting features in B-lineage childhood acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 1989; 74: 1252–1259
   PubMed Web of Science ®Google Scholar
• Pui C.-H., Simone J. V., Hancock M. L., Evans W. E., Williams D. L., Bowman W. P., Dahl G. V., Dodge R. K., Ochs J., Abromowitch M., Rivera G. K. Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: Long-term results of St Jude Total Therapy Study X. Leukemia 1992; 6: 150–157
   PubMed Web of Science ®Google Scholar
• Sather H., Miller D., Nesbit M., Heyn R., Hammond D. Differences in prognosis for boys and girls with acute lymphoblastic leukaemia. Lancet 1981; 739–743
   PubMed Web of Science ®Google Scholar
• Lilleyman J. S., Hann I. M., Stevens R. F., Eden O. B. French American British (FAB) morphological classification of childhood lymphoblastic leukaemia and its clinical importance. J. Clin. Pathol. 1986; 39: 998–1002
   PubMed Web of Science ®Google Scholar
• Wagner V. M., Baehner R. L. Correlation of the FAB morphologic criteria and prognosis in acute lymphocytic leukemia of childhood. Am. J. Pediatr. Hematol./Oncol. 1979; 1: 103–106
   PubMedGoogle Scholar
• Lilleyman J. S., Hann I. M., Stevens R. F., Richards S. M., Eden O. B., Chessels J. M., Bailey C. C. Cytomoiphology of childhood lymphoblastic leukaemia: a prospective study of 2000 patients. Br. J. Haematol. 1992; 81: 52–57
   PubMed Web of Science ®Google Scholar
• Van Der Does-Van Den Berg A., Van Wering E. R., Suciu S., Solbu G., Van T Veer M. B., Rammeloo J. A., De Koning J., Van Zanen G. E. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and I-asparaginar, for standard risk childhood acute lymphocytic leukemia: Results of a Dutch Phase III study (ALL V). Am. J. Pediatr. Hematol./Oncol. 1989; 11: 125–133
   PubMedGoogle Scholar
• Greaves M. F., Janossy G., Peto J., Kay H. Immunologically defined subclasses of acute lymphoblastic leukaemia in children: their relationship to presentation features and prognosis. Br. J. Haematol. 1981; 48: 179–197
   PubMed Web of Science ®Google Scholar
• Pui C.-H., Williams D. L., Raimondi S. C., Melvin S. L., Behn F. G., Look A. T., Dahl G. V., Rivera G. K., Kalwinsky D. K., Mirro J., Dodge R. K., Murphy S. B. Unfavorable presenting clinical and laboratory features are associated with calla-negative non-T, non-B lymphoblastic leukemia in children. Leuk. Res. 1986; 10: 1287–1292
   PubMed Web of Science ®Google Scholar
• Sallan S. E., Ritz J., Pesando J., Gelber R., O'Brien C., Hitchcock S., Coral F., Schlossman S. F. Cell surface antigen: Prognostic implications in childhood acute lymphoblastic leukemia. Blood 1980; 55: 395–402
   PubMed Web of Science ®Google Scholar
• Vannier J. P., Bene M. C., Faure G. C., Bastard C., Garand R., Bernard A. Investigation of the CD10 (cALLA) negative acute lymphoblastic leukameia: further description of a group with a poor prognosis. Br. J. Haematol. 1989; 72: 156–160
   PubMed Web of Science ®Google Scholar
• Crist W. M., Carroll A. I., Shuster J. J., Behm F. G., Whitehead M., Vietti T. J., Look A. T., Mahoney D., Ragab A., Pullen D. J., Land V. J. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19) (q23;p13): a Pediatric Oncology Group study. Blood 1990; 76: 117–122
   PubMed Web of Science ®Google Scholar
• Lilleyman J. S., Hinchcliffe R. F. Pre-B and ‘common’ lymphoblastic leukaemia of childhood compared. Br. J. Haematol. 1989; 71: 227–231
   PubMed Web of Science ®Google Scholar
• Raimondi S. C., Behm F. G., Roberson P. K., Williams D. L., Pui C.-H., Crist W. M., Look A. T., Rivera G. K. Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19). J. Clin. Oncol. 1990; 8: 1380–1388
   PubMed Web of Science ®Google Scholar
• Van Wering E. R., Van'T Veer M. B., Akkerboom J. C., Vissers-Praalder E. C., Pinkster T., De Waal F. C. The significance of the white blood cell count and of immunological typing for the prognosis of acute lymphatic leukaemia in children. Ned. Tijdschr. Geneeskd. 1986; 130: 165–169
   Google Scholar
• Costlow M. E., Pui C.-H., Dahl G. V. Glucocorticoid receptors in childhood acute lymphoblastic leukemia. Cancer Res. 1982; 42: 4801–4806
   PubMed Web of Science ®Google Scholar
• Konior-Yarbro G. S., Lippman M. E., Johnson G. E., Leventhal B. G. Glucocorticoid receptors in subpopulations of childhood acute lymphocytic leukemia. Cancer Res. 1977; 37: 2688–2695
   PubMed Web of Science ®Google Scholar
• Quddus F. F., Leventhal B. G., Boyett J. M., Pullen D. J., Crist W. M., Borowitz M. J. Glucocorticoid receptors in immunological subtypes of childhood acute lymphocytic leukemia cells: A Pediatric Oncology Group study. Cancer Respondent. 1985; 45: 6482–6486
   PubMed Web of Science ®Google Scholar
• Vogler L. B., Crist W. M., Sarrif A. M., Pullen J., Bartolucci A. A., Falletta J. M., Dowell B., Humphrey G. B., Blackstock R., Van Eys J., Metzgar R. S., Cooper M. D. An analysis of clinical and laboratory features of acute lymphocytic leukemias with emphasis on 35 children with pre-B leukemia. Blood 1981; 58: 135–140
   PubMed Web of Science ®Google Scholar
• Evans W. E., Petros W. P., Relling M. V., Crom W. R., Madden T., Rodman J. H., Sunderland M. Clinical pharmacology of cancer chemotherapy in children. Pediatr. Clin. North Am. 1989; 36: 1199–1230
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Raza A., Larson R., Goldberg J., Tricot G., Carey M., Kukla C. Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: A review of three consecutive trials of the treatment of poor prognosis patients. Leuk. Res. 1991; 15: 713–780
   Web of Science ®Google Scholar
• Kokenberg E., Sonneveld P., Sizoo W., Hagenbeek A., Löwenberg B. Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia. J. Clin. Oncol. 1988; 6: 802–812
   PubMed Web of Science ®Google Scholar
• Nooter K., De Vries A., Martens A. C. M., Hagenbeek A. Effect of cyclophosphamide pretreatment on daunorubicin in rat acute leukaemia model. Eur. J. Cancer 1990; 26: 729–732
   PubMed Web of Science ®Google Scholar